VANCOUVER, [May 5, 2021] — Segra International Corp, a leading cannabis agriculture technology company, is pleased to announce its first successful shipment of numerous premium Cannabis cultivars to one of the first licensed medical cannabis producers in Germany. Under the licensing agreement, Segra's team has curated specific cultivars to meet the chemical potency range requirements necessary to produce licensed medical cannabis in Germany.
"Segra's Verified Segra-Stock plantlets offer medical cannabis cultivators the option to introduce genetics to their facilities while maintaining phytosanitary standards for pharmaceutical-grade cannabis cultivation," said Jamie Blundell, CEO of Segra International. "Building on our recent shipments to South Africa, this agreement again demonstrates Segra's ability to fulfill plantlet orders from our lab in Vancouver to literally any corner of the globe. Our distribution model builds upon a well-established global regulatory system developed by agricultural titans such as Dole Fruit and Driscoll's companies. This model makes it possible for tissue culture plants to ship internationally in full compliance with phytosanitary import restrictions. Furthermore, contrary to the huge hurdles cannabis licensed producers face in exporting dry flowers and formulary cannabis products, our young plant products are being welcomed by federal regulators in emerging cannabis markets. This is especially true with regulators who see the critical importance that their nation's growers have access to clean stock from top-performing cultivars against the backdrop of an increasingly competitive cannabis industry landscape."
Segra is an agriculture technology company offering plant tissue culture, plant genomics, and pathogen detection services to accelerate the advancement of the cannabis industry. The company's proprietary technologies empower its clients to drive financial performance and mitigate risk while exploring the next frontier of optimized cultivation practices for the rapidly evolving cannabis consumer. Segra has developed industrial-scale laboratories to produce Verified Segra-Stock, robust, and DNA-fingerprinted cannabis plantlets for licensed producers globally. To support this vision, Segra has assembled a world-class team of specialists in the fields of agronomy, molecular genetics, plant tissue culture, and regulatory compliance. Learn more at www.segra-intl.com
For Further Information:
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except